MGO One Seven’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $374K | Sell |
9,876
-14
| -0.1% | -$645 | 0.01% | 1106 |
|
|
2026
Q2 | $474K | Buy |
9,890
+2,101
| +27% | +$90.3K | 0.01% | 1000 |
|
|
2026
Q1 | $286K | Sell |
7,789
-1,210
| -13% | -$57.3K | 0.01% | 1154 |
|
|
2025
Q4 | $458K | Sell |
8,999
-16,037
| -64% | -$820K | 0.01% | 911 |
|
|
2025
Q3 | $1.39M | Sell |
25,036
-25,118
| -50% | -$1.47M | 0.03% | 499 |
|
|
2025
Q2 | $3.46M | Buy |
50,154
+32,432
| +183% | +$2.21M | 0.11% | 204 |
|
|
2025
Q1 | $1.23M | Sell |
17,722
-2,344
| -12% | -$194K | 0.05% | 387 |
|
|
2024
Q4 | $1.73M | Buy |
20,066
+2,413
| +14% | +$261K | 0.07% | 306 |
|
|
2024
Q3 | $2.1M | Sell |
17,653
-2,146
| -11% | -$286K | 0.09% | 241 |
|
|
2024
Q2 | $2.83M | Buy |
19,799
+3,629
| +22% | +$481K | 0.13% | 175 |
|
|
2024
Q1 | $2.08M | Sell |
16,170
-1,460
| -8% | -$174K | 0.11% | 212 |
|
|
2023
Q4 | $1.82M | Buy |
17,630
+600
| +4% | +$59.3K | 0.1% | 217 |
|
|
2023
Q3 | $1.55M | Buy |
17,030
+1,436
| +9% | +$126K | 0.12% | 194 |
|
|
2023
Q2 | $1.26M | Sell |
15,594
-912
| -6% | -$74.5K | 0.12% | 209 |
|
|
2023
Q1 | $1.31M | Buy |
16,506
+734
| +5% | +$52K | 0.08% | 254 |
|
|
2022
Q4 | $1.07M | Buy |
15,772
+150
| +1% | +$8.79K | 0.11% | 215 |
|
|
2022
Q3 | $778K | Sell |
15,622
-1,646
| -10% | -$88.2K | 0.03% | 290 |
|
|
2022
Q2 | $962K | Sell |
17,268
-9,156
| -35% | -$508K | 0.13% | 179 |
|
|
2022
Q1 | $1.13M | Sell |
26,424
-376
| -1% | -$19.3K | 0.12% | 193 |
|
|
2021
Q4 | $1.16M | Buy |
26,800
+2,064
| +8% | +$112K | 0.12% | 203 |
|
|
2021
Q3 | $1.03M | Buy |
24,736
+2,216
| +10% | +$107K | 0.13% | 194 |
|
|
2021
Q2 | $690K | Buy |
22,520
+332
| +1% | +$12.9K | 0.1% | 263 |
|
|
2021
Q1 | $544K | Sell |
22,188
-1,338
| -6% | -$47.7K | 0.09% | 278 |
|
|
2020
Q4 | $611K | Buy |
23,526
+6
| +0% | +$207 | 0.13% | 217 |
|
|
2020
Q3 | $607K | Sell |
23,520
-370
| -2% | -$12.3K | 0.14% | 184 |
|
|
2020
Q2 | $585K | Buy |
23,890
+6,580
| +38% | +$210K | 0.15% | 187 |
|
|
2020
Q1 | $521K | Buy |
17,310
+1,062
| +7% | +$31.6K | 0.18% | 161 |
|
|
2019
Q4 | $470K | Buy |
+16,248
| New | +$450K | 0.12% | 229 |
|
|
2019
Q1 | – | Sell |
-2,004
| Closed | -$46K | – | 1227 |
|
|
2018
Q4 | $46K | Buy |
+2,004
| New | +$44.5K | 0.02% | 656 |
|
|
2018
Q1 | $56K | Sell |
2,288
-1,400
| -38% | -$36.8K | 0.03% | 585 |
|
|
2017
Q4 | $99K | Buy |
+3,688
| New | +$93.8K | 0.05% | 440 |
|
Other funds holding NVO
MGO One Seven's NVO Position: Q3 2026 in Review
MGO One Seven reduced its Novo Nordisk (NVO) stake by 0.14% in Q3 2026, selling an estimated $645 and leaving 9,876 shares worth $374K. The position accounts for 0.01% of the portfolio, ranked #1106.
MGO One Seven first reported a position in NVO in Q4 2017 and has held it in 31 quarters since. The position peaked at $3.46M in Q2 2025. 1,091 funds tracked by Wall St. Rank hold NVO as of Q3 2026.
- MGO One Seven held 9,876 shares of Novo Nordisk worth $374K as of Q3 2026.
- MGO One Seven sold 14 Novo Nordisk shares in Q3 2026, an estimated $645.
- Novo Nordisk made up 0.01% of MGO One Seven's portfolio in Q3 2026, its #1106 holding.
- MGO One Seven first reported a position in Novo Nordisk in Q4 2017 and has held it in 31 quarters since.
- MGO One Seven's Novo Nordisk position peaked at $3.46M in Q2 2025.
- 1,091 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.
Based on MGO One Seven's 13F filing for Q3 2026, filed 28 Oct 2026.